Telix Pharmaceuticals (ASX:TLX) has announced that the last patient has been imaged in a phase one clinical study of the company's investigational prostate cancer imaging product TLX591-CDx. …
Telix Japanese prostate cancer imaging study completes enrolment
September 9, 2021 Australian Biotech
Latest Video
New Stories
-
AZ to maintain breast cancer therapy on the PBS for six months despite price rise knocked back
September 24, 2026 - -
England's genomics chief to share NHS lessons during Australia visit
September 24, 2026 - - Latest News -
AbbVie’s top lawyer publicly makes the case against German pricing
September 24, 2026 - -
AI is already in the decision-making process, but where is the conversation about its use?
September 24, 2026 - -
Blood test for eight cancers arrives in Australia, but misses almost half of them
September 23, 2026 - -
Prescient raises $6 million to carry cancer drug PTX-100 past a key dosing decision
September 23, 2026 - - Australian Biotech -
Seven Australian startups share $15.6 million to take on dementia
September 23, 2026 - - Australian Biotech